INTERSTITIAL THERMORADIOTHERAPY WITH FERROMAGNETIC IMPLANTS FOR LOCALLY ADVANCED AND RECURRENT NEOPLASMS
INTERSTITIAL THERMORADIOTHERAPY WITH FERROMAGNETIC IMPLANTS FOR LOCALLY ADVANCED AND RECURRENT NEOPLASMS
复制标题
DOI：
10.1016/0360-3016(93)90427-w
复制
发表时间：
1993-09-01
影响因子：
7
通讯作者：
CETAS, TC
中科院分区：
文献类型：
--
作者：
MACK, CF;STEA, B;CETAS, TC
Purpose: The University of Arizona, University of California at San Francisco, City of Hope Medical Center, and University of Wisconsin participated in a Phase I/II protocol to assess the heating ability and the toxicity of interstitial thermoradiotherapy using ferromagnetic implantation.Methods and Materials: Forty-four patients with advanced primary or recurrent extra-cranial solid malignancies were enrolled in this study. Fourteen gauge catheters were implanted into tumors and, once in the department of Radiation Oncology, loaded with ferromagnetic seeds to deliver a 60 min hyperthermia treatment. Multi-point thermometry was continuously used throughout the heating sessions for all patients, sampling the periphery as well as the core of the tumor. After Iridium-192 brachytherapy, 18 patients then had an additional treatment. The mean radiation dose while on protocol was 50.0 Gy, with total doses (including prior radiotherapy) ranging from 20.3-151.8 Gy (median = 88.7 Gy). Response and toxicity were assessed by inspection, palpation, and/or radiologic studies. Forty-one patients were evaluable for response, and there were 55 analyzable hyperthermia treatment sessions.Results: The complete response rate was 61% (25/41). The partial response rate was 31.7% and only 7.3% failed to respond. Median duration of local control has not yet been reached. The mean maximum, minimum, and mean time-averaged temperatures for all in-tissue sensors were 43.7-degrees-C, 38.7-degrees-C, and 41.0-degrees-C, respectively. Tumor size was the only factor significantly correlated with temperatures or with complete response rate; larger tumors attained higher temperatures but smaller tumors had a higher response probability. Nineteen patients (43%) experienced toxicities, however there was only a 7% (3/44) rate of serious complications (Grade 3 or 4). Prior treatment with hyperthermia was the only factor significantly correlated with serious toxicity.Conclusion: These results, a 93% total response with only 7% serious toxicity, are encouraging especially in the context of the patient population treated. Phase II/III studies involving ferromagnetic implantation are warranted.
